Member Info for pomander

I agree with that synopsis Bignose - my only difficulty is squaring it with 3 biilion traded in a couple of weeks post UK launch.Would appear that was not all down to day traders. As for significance how many day taders would have understood siginificance of protecting the EMA approval ?

Was hoping & expecting for stronger market reaction.

Alq- I believe that you are reading the RNS incorrectly and your claim that Recordati have never shared a launch plan is without foundation, unless of course you are going to enlighten us all with your connection (if any ) to Recordati and/or Ple. The RNS clearly states ''it now follows that following the first commercial sale of Fortacin™ in each of France, Germany, Italy, Portugal and Spain, ''scheduled''for March 2018'' The ''anticipation '' bit is in reference to PSNW being able to meet Recordati's intial launch supply requirements for the scheduled March 2018 launch across the 5 territories. Given manufacturing is underway and the expanded batch size compliant it would seem reasonable to assume that the scheduled launch across the 5 territories will be met in March 2018.

''Visible operational activities'' - now there speaks a consultant !

Yes Indeed Prof - the share price action to follow should be most interesting. All things being equal we should see volumes close to those post the UK launch - this is to my mind a more significant milestone. If this does not happen I will view it as supportive of a stake built post UK launch - in which case its looking rosy under both scenario's.

Also kicks into touch Alq's theory that the EU launch would be on a single teritroy basis (Italy or Germany his best bets) pending patient feedback data before further launches. Seems Recordati have taken steps to get the launch spot on which again is positive or why bother and why give up exclsuivity for the sort of mumbers Alq and there own presentations have shown. The price point will indeed be very interesting - sometimes the non- experts do get it right ! There was certainly consensus here that £59.99 or £100 for 20 doses was too high. Lets hope Alq right about one thing - launch will be early March and announced at the conference!

Top sniffing Bignose - I should have gone back to the original RNS - as my wife keeps reminding me, I only remember 'half the story'. Will be interesting to see where they pitch the unit price. All looks finally set now to begin to attract both traders and long term investors - just a little surprised this is not already happening, unless of course the long termers or a potential suitor took their seats post the UK launch.

Bignose - I agree with you on the reasons for the UK price reduction and doubt very much if the EU launch price will be anywhere near that level. Only provisio being would be if Fortacin began flying off the shelf post the reduction, Recordati might take notice, although I suspect that would stil only result in a smaller price reduction. I am not sure thre is any direct link beetween tripling the batch size and the price point. Obvioulsy scale drives a higher margin per unit and provides scope to reduce the price point without massivley impacting the bottom line. The comment from RP was that the batch size was being increased to meet the anticipated increase in demand, but that will not be immediate, so the smaller batch size will suffice to meet initial demand post launch- as I understand it.

Very difficult stock to fathom- chuggs along at 2-3 m traded per day then for seemingly no reason jumps to 18m and 4.5% rise.

Yeep , thais what the HKSE indicates, but amounts nvolved are tiny in comparison to existing holdigs. It was more Combra who I initally thought hads sold that caught my attention.

The Director sells listed on teh HKES on 1/10/2107 are due to theexpiry or cancellation without exercise of equity derivatives under which they had a right to take the underlying shares. Alternatively - 13-00-00-1-10-17 - Da Vinci Code, and as Bignose sniffed out, this all happened on the Sun Day, or Holy Day. Watch out for a premonition of Mary Magdalane in your sleep as we seek the Holy Grail.

Would seem to the answer- The number of shares in which you are interested has reduced because: expiry or cancellation without exercise of equity derivatives under which (choose one): you had a right to take the underlying shares

Now there's a thought !

From memory someone did post positively on here having tried it - it may have been SORR but not sure about that

Bignose- Mr Comba was not alone divesting on the Lord's day and the day of ressurection. Seriously though, its quite odd that they would all sell at the same time. Almost as if it were arranged and as you say was the 1/10/2017 (Sunday) used on (perhaps mistakenely) the transfer form if an off market disposal which seems likeley? Comba Charles David Andrew 500,000(L) 12041(L) 0(L) 01/10/2017 Gibson Jamie Alexander 1,300,000(L) 12041(L) 69,208,513(L) 3.77(L) 01/10/2017 Mellon James 1,300,000(L) 12041(L) 387,386,211(L) 21.09(L) 01/10/2017

C. David Andrew Comba- Independent Non-Executive Director Sold his holding of 500,000 om 1st Oct 2017 - hardly a positive sign unless having problems meeting the mortgage !

I confess to being unable to rfatom teh dark secrets of the workings of the HK SE, but all things being equal the EU launch should have a greatre positive impact of the share rice than the UK launch. I don't appraoch this from the share price level, but from the market cap and at 72 cents or circa US$160 m that's still very modest if you buy into the potential global commerical opportunity for Fortacin. I also believe, and I appreciate many disagree with me, that an undisclosed stake was built post UK launch.

Big correction 4.25 US $ so 3.2p - 12.5% premium to today's price.

Billings Services or ticker BILL on AIM was once held by RP until JM bought them from the company. It has announced a tender offer to buy back up to 41% of the company's shares at 4.25 p per share. I have bought some at 2.8 p and will add as seems an easy turn to make due to no interest in stock.

Bignose- I think goobledegook from JG if he said that - more likely its small mkt cap might be a factor. The only sign of any material interest was post the UK launch.Now we are back to 5% swings on less than 10 m traded, so liquidity has dried up.